These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28437834)

  • 1. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
    Korth-Bradley J; Rupon J; Plotka A; Charnigo R; Rendo P
    Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
    Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
    Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
    Delavenne X; Dargaud Y; Ollier E; Négrier C
    Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
    Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
    J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
    Shafer F; Charnigo RJ; Plotka A; Baumann J; Liang Y; Korth-Bradley J
    Clin Pharmacol Drug Dev; 2015; 4(3):237-41. PubMed ID: 27140804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.
    McEneny-King A; Chelle P; Foster G; Keepanasseril A; Iorio A; Edginton AN
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):411-426. PubMed ID: 31104228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
    Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
    Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
    Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
    Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.